awmsg logo



adalimumab (Humira®)


Reference No. 2562

Publication date:
09/06/2015


Appraisal information

adalimumab (Humira®) 40 mg/0.8 ml solution for injection


Company: AbbVie Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 18/03/2015
AWMSG meeting date: 22/04/2015
   
   
Submission Type: Limited Submission
Status: Superseded
Advice No: 1015
Ministerial ratification: 08/06/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download